BHV-1420

BHV-1420 is an investigational extracellular protein degrader developed by Biohaven for the treatment of membranous nephropathy. Utilizing Biohaven's proprietary TRAP (Target-specific Receptor Ab-binding Proteolysis) platform, BHV-1420 is designed to selectively target and degrade autoantibodies directed against the Phospholipase A2 receptor (PLA2R), which are the primary pathogenic drivers in approximately 70-80% of patients with primary membranous nephropathy. The molecule is a bifunctional degrader that binds to the pathogenic PLA2R autoantibodies and directs them to cellular receptors for lysosomal degradation, effectively clearing them from the systemic circulation. This approach aims to provide a targeted therapeutic effect by removing specific disease-causing antibodies while avoiding the broad B-cell depletion and systemic immunosuppression associated with current standard-of-care treatments like rituximab or cyclophosphamide.